JP2005511594A5 - - Google Patents

Download PDF

Info

Publication number
JP2005511594A5
JP2005511594A5 JP2003541838A JP2003541838A JP2005511594A5 JP 2005511594 A5 JP2005511594 A5 JP 2005511594A5 JP 2003541838 A JP2003541838 A JP 2003541838A JP 2003541838 A JP2003541838 A JP 2003541838A JP 2005511594 A5 JP2005511594 A5 JP 2005511594A5
Authority
JP
Japan
Prior art keywords
alkyl
group
alkoxy
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003541838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511594A (ja
Filing date
Publication date
Priority claimed from SE0103767A external-priority patent/SE0103767D0/xx
Application filed filed Critical
Priority claimed from PCT/SE2002/002019 external-priority patent/WO2003039547A1/en
Publication of JP2005511594A publication Critical patent/JP2005511594A/ja
Publication of JP2005511594A5 publication Critical patent/JP2005511594A5/ja
Pending legal-status Critical Current

Links

JP2003541838A 2001-11-09 2002-11-06 肥満の治療における、もしくは摂食量の減少のためのスルホンアミド誘導体の使用 Pending JP2005511594A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0103767A SE0103767D0 (sv) 2001-11-09 2001-11-09 New use
US35689002P 2002-02-13 2002-02-13
PCT/SE2002/002019 WO2003039547A1 (en) 2001-11-09 2002-11-06 Use of sulfonamide derivatives in the treatment of obesity or for the reduction of food intake

Publications (2)

Publication Number Publication Date
JP2005511594A JP2005511594A (ja) 2005-04-28
JP2005511594A5 true JP2005511594A5 (US06894165-20050517-C00155.png) 2006-01-05

Family

ID=26655592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541838A Pending JP2005511594A (ja) 2001-11-09 2002-11-06 肥満の治療における、もしくは摂食量の減少のためのスルホンアミド誘導体の使用

Country Status (6)

Country Link
US (1) US20030166663A1 (US06894165-20050517-C00155.png)
EP (1) EP1450806B1 (US06894165-20050517-C00155.png)
JP (1) JP2005511594A (US06894165-20050517-C00155.png)
AT (1) ATE429916T1 (US06894165-20050517-C00155.png)
DE (1) DE60232173D1 (US06894165-20050517-C00155.png)
WO (1) WO2003039547A1 (US06894165-20050517-C00155.png)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1897876A3 (en) * 2002-06-20 2009-03-18 Biovitrum AB (publ) Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP1809619A1 (en) * 2004-10-21 2007-07-25 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
CN101258136A (zh) * 2005-07-05 2008-09-03 阿斯利康(瑞典)有限公司 新化合物、其制备方法、中间体、药物组合物和其在治疗5-ht6介导的疾病例如阿尔茨海默病、认知障碍、精神分裂症相关的认知缺损、肥胖和帕金森病中的用途
US20100105657A1 (en) * 2005-07-05 2010-04-29 Astrazeneca Ab Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease
JP4434182B2 (ja) 2006-07-25 2010-03-17 セイコーエプソン株式会社 眼鏡レンズの設計方法
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0689536T3 (da) 1993-03-16 2001-07-30 Pfizer Naphthalenderivater
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
AU2790999A (en) * 1998-03-03 1999-09-20 Merck & Co., Inc. Fused piperidine substituted arylsulfonamides as beta3-agonists
TWI222450B (en) * 1999-07-28 2004-10-21 Upjohn Co Oxazinocarbazoles for the treatment of CNS diseases
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
US6399617B1 (en) * 2000-07-21 2002-06-04 Biovitrum Ab Use

Similar Documents

Publication Publication Date Title
JP2005511594A5 (US06894165-20050517-C00155.png)
JP6506836B2 (ja) B型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
JP2007517044A5 (US06894165-20050517-C00155.png)
JP2008514611A5 (US06894165-20050517-C00155.png)
JP2011524422A5 (US06894165-20050517-C00155.png)
JP2006507355A5 (US06894165-20050517-C00155.png)
CN112867721A (zh) Sting激动性化合物
JP2006524222A5 (US06894165-20050517-C00155.png)
JP2007511504A5 (US06894165-20050517-C00155.png)
ATE374763T1 (de) Bisarylsulfonamid-derivate und ihre verwendung für krebs therapie
JP2004516314A5 (US06894165-20050517-C00155.png)
JP2010501478A5 (US06894165-20050517-C00155.png)
DE69710319T2 (de) Para-substituierte phenylpropansäure derivate als integrin-antagonisten
JP2007517035A5 (US06894165-20050517-C00155.png)
JP2006500394A5 (US06894165-20050517-C00155.png)
WO2006069525A1 (fr) Composes d’aminopyrimidine et leurs sels, procede pour la preparation et l’utilisation pharmaceutique de ceux-ci
JP2008514732A5 (US06894165-20050517-C00155.png)
CN1152870A (zh) 杂环化合物作为多巴胺d3配位体的用途
RU2007116987A (ru) Новые соединения
JP2011527334A5 (US06894165-20050517-C00155.png)
JP2005527542A5 (US06894165-20050517-C00155.png)
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
JP2006515339A5 (US06894165-20050517-C00155.png)
JP2005508962A5 (US06894165-20050517-C00155.png)
JP2002030084A5 (US06894165-20050517-C00155.png)